8
Participants
Start Date
June 8, 2007
Primary Completion Date
August 10, 2007
Study Completion Date
August 10, 2007
14C-SB649868
SB-649868 will be provided as powder in a bottle which will be reconstituted into a solution prior to dosing via a hard gelatin capsule. Each subject will receive one unit dose of SB-649868 30 milligram reconstituted powder presented in a size 00 capsule once. The capsule will be swallowed with 160 milliliters of water.
GSK Investigational Site, Tranent
Lead Sponsor
GlaxoSmithKline
INDUSTRY